Developing small molecules to improve cancer treatment by targeting CD47

Quantitative High Throughput Screening for Small Molecules Targeting CD47 in Cancer

NIH-funded research Institut Jean Paoli & Irene Calmettes Centre Regional de Lutte Contre Le Cancer · NIH-10557909

This study is looking for new tiny medicines that can help your immune system fight cancer better by blocking a specific interaction between two proteins, which could lead to more effective treatments with fewer side effects for people with tumors.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionInstitut Jean Paoli & Irene Calmettes Centre Regional de Lutte Contre Le Cancer NIH-funded
Lab location1 site (Marseille 9e Arrondissement, France)
Project IDNIH-10557909 on NIH RePORTER

What this research studies

This research focuses on developing small molecules that can effectively block the interaction between the immune checkpoint protein CD47 and its receptor SIRPα, which is crucial for enhancing the body's anti-tumor immune response. By targeting this interaction, the research aims to improve the selectivity of treatments for tumors while reducing side effects like anemia. The approach involves high throughput screening to identify promising small molecules that can penetrate solid tumors more effectively and lead to better treatment outcomes for cancer patients. If successful, this could provide a new avenue for cancer immunotherapy.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with solid tumors or hematological cancers that express high levels of CD47.

Not a fit: Patients with non-cancerous conditions or those whose tumors do not express CD47 may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective and less toxic cancer treatments for patients.

How similar studies have performed: Other research has shown promise in targeting immune checkpoints with small molecules, but this specific approach targeting CD47 is relatively novel.

Where this research is happening

Marseille 9e Arrondissement, France

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.